PLYMOUTH MEETING, Pa. – Hycult Biotech Inc., a wholly owned Subsidiary of Hycult Biotech B.V., a provider of innovative immunology and cell biology solutions, has named Mr. Dino DiCamillo as Executive Director, of its newly incorporated U.S. Subsidiary.

“I am proud to play a role in the development and execution of Hycult’s local strategy”

.Mr. DiCamillo brings extensive expertise and experience in the areas of immunology, genomics, proteomics, and business operations and management. He currently serves as President and CEO of Percorso Life Sciences, where he partners with early stage technology companies and provides direction and leadership to companies looking to establish a U.S. presence. More recently, Mr. DiCamillo served as Vice President and Officer of Advanced Research Technologies, President of Alfa Wassermann Proteomics, Vice President of Environmental Diagnostics at Invitrogen, and President of Dynal Biotech Inc, where he provided strategic leadership and execution in a variety of roles.

“As a business leader and industry expert, Mr. DiCamillo brings to Hycult Biotech Inc. a deep understanding of operations necessary to support a local subsidiary,” said Mr. Rik van Heijningen, Managing Director of Hycult Biotech B.V. “His expertise with new technology adoption, operations, and channel management will assist Hycult Biotech Inc. execute its local strategy.”

“I am proud to play a role in the development and execution of Hycult’s local strategy,” said Mr. DiCamillo. “Hycult Biotech offers a broad and unique technology specific to researchers who focus on the innate immune system, which facilitates the understanding of the immune system paradigm.”

About Hycult Biotech:

Hycult Biotech is a leader in the fields of immunology and cell biology, we develop, produce and market antibodies, antibody based products and more specifically immunoassays for innate immunity and directly related fields, with an emphasis on complement, neutrophil proteins, TLR, scavenger receptors and acute phase proteins. Furthermore, we have a strong interest in progressing research in the area of inflammation and cell damage caused by pathogens or oxidation factors.